Unlock instant, AI-driven research and patent intelligence for your innovation.

HCV Inhibitors And Methods Of Using Them

a technology of hcv and inhibitors, which is applied in the direction of heterocyclic compound active ingredients, biocides, drug compositions, etc., can solve the problems of long-term improvement of hepatitis c, and achieve the effect of increasing the sustained response ra

Inactive Publication Date: 2007-06-28
RIGEL PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, longterm improvement in hepatitis C occurs only if HCV RNA disappears during therapy and stays undetectable once therapy is stopped.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HCV Inhibitors And Methods Of Using Them
  • HCV Inhibitors And Methods Of Using Them
  • HCV Inhibitors And Methods Of Using Them

Examples

Experimental program
Comparison scheme
Effect test

example 1

Assay Example 1

HCV Replicon Assay

[0123] Actively dividing 5-2Luc replicon cells were seeded at the density of 5000-7500 cells / well in the volume of 90 μl / well into 96 well plate(s). The cells were then incubated at 37° C. and 5% CO2 for 24 hours The 5-2 cells are replicon cells licensed from Ralf Bartenschlager (Germany) and have a self-replicating RNA molecule in the Huh7 cell; the RNA contains HCV non-structural proteins that make the self-replication possible.

[0124] Various concentrations of compounds (in the volume of 10 μl) were added into each well 24 hours after seeding the cells. The cells were incubated for another 24 hours before luciferase assay.

[0125] After incubating the 5-2Luc replicon cells with the compounds for 24 hours, media were aspirated from each well and Bright-Glo (Pharmacia) luciferase assay reagents were added to each well according to the manufacturer's manual. Briefly, the BrightGlo reagent was diluted with equal volume of PBS and an aliquote (100 μl) ...

example 2

Assay Example 2

Luciferase Counter Assay

[0126] Actively dividing CMV-Luc cells (Luc cells in which DNA construct (CMV promoter followed by Luciferase gene) is permanently integrated into the chromosome of Huh7 cells) were seeded at the density of 5000-7500 cells / well in the volume of 90 μl / well into 96 well plate(s). The cells were then incubated at 37° C. and 5% CO2 for 24 hours.

[0127] Various concentrations of compounds (in the volume of 10 μl) were added into each well 24 hours after seeding the cells. The cells were incubated with the compounds for another 24 hours before luciferase assay.

[0128] After incubating the CMV-Luc cells with the compounds for 24 hours, media were aspirated from each well and Bright-Glo (Pharmacia) luciferase assay reagents were added to each well according to the manufacturer's manual. Luciferase counts were taken using a luminometer.

[0129] The activity of a number of compounds according to the invention measured by the luciferase assay is displayed...

example 3

Assay Example 3

Immunoblotting Assay

[0130] Actively dividing 9-13 replicon cells (Huh7 cells comprising an HCV replicon) were seeded at the density of 1×105 cells / well in the volume of 2 ml / well into 6 well plate(s), The cells were then incubated at 37° C. and 5% CO2 for 24 hours.

[0131] Various concentrations of compounds (in the volume of 10 μl) were added into each well 24 hours after seeding the cells. The cells were incubated with the compounds for another 48 hours.

[0132] Protein samples were prepared from the cultured cells and resolved on a SDS-PAGE gel.

[0133] After electrophoresis, the protein samples on the SDS-PAGE gel were transferred to a nitrocellulose membrane.

[0134] The membrane was blocked with 5% non-fat milk in PBS for 1 hr at room temperature.

[0135] Primary antibody incubation was performed for 1 hour at room temperature before the membrane was washed for 3 times with PBST (PBS plus 0.1% Tween 20), 15 minutes each.

[0136] Horse Radish Peroxidase conjugated sec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
body weightaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 10 / 951,181 filed Sep. 27, 2004, which claims priority from U.S. Provisional Patent Application No. 60 / 506,556, filed on Sep. 26, 2003 and from U.S. Provisional Patent Application No. 60 / 576,536, filed on Jun. 3, 2004.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention is in the field of small molecule inhibitors of HCV and methods of using them to inhibit HCV. [0004] 2. Summary of the Related Art [0005] The hepatitis C virus (HCV) is one of the most important causes of chronic liver disease in the United States. It accounts for about 15 percent of acute viral hepatitis, 60 to 70 percent of chronic hepatitis, and up to 50 percent of cirrhosis, end-stage liver disease, and liver cancer. Almost 4 million Americans, or 1.8 percent of the U.S. population, have antibody to HCV (anti-HCV), indicating ongoing or previous infection with the virus. Hepatitis C causes an estimate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377C07D471/02A61K31/4745A61K31/4709A61P31/12C07D215/54C07D471/04C07D471/14C07D491/14
CPCC07D471/04C07D471/14C07D491/14A61P1/16A61P31/12
Inventor THOTA, SAMBAIAHARGADE, ANKUSHSINGH, RAJINDERLU, HENRY H.HUANG, PEIYONG
Owner RIGEL PHARMA